CKD-504 in SAD and MAD in Healthy Korean and Caucasian Adult Male and Female Subjects

PHASE1UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 23, 2018

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions

Huntington Disease

Interventions

DRUG

CKD-504

orally administered once with investigational drug assigned on 1d morning with 240 mL of water

DRUG

Placebo

orally administered

Trial Locations (1)

RECRUITING

Seoul National University Hospital, Seoul